National Bank of Canada’s CorMedix CRMD Stock Holding History

National Bank of Canada’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2	Closed	-$16	–	2982
2024 Q3	$16	Buy	+2	New	+$11	﹤0.01%	2659

Other funds holding CRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FTM

First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

National Bank of Canada's CRMD Position: Q4 2024 in Review

National Bank of Canada sold out of CorMedix (CRMD) in Q4 2024, closing a stake of 2 shares — an estimated $16 sold.

National Bank of Canada first reported a position in CRMD in Q3 2024 and held it in 1 quarter. The position peaked at $16 in Q3 2024. 129 funds tracked by Wall St. Rank hold CRMD as of Q4 2024.

National Bank of Canada reported no remaining CorMedix position as of Q4 2024 after selling out during the quarter.
National Bank of Canada sold 2 CorMedix shares in Q4 2024, an estimated $16.
National Bank of Canada first reported a position in CorMedix in Q3 2024 and held it in 1 quarter.
National Bank of Canada's CorMedix position peaked at $16 in Q3 2024.
129 funds tracked by Wall St. Rank held CorMedix as of Q4 2024.

Based on National Bank of Canada's 13F filing for Q4 2024, filed 12 Feb 2025.